FYERS
Home
/
Stocks
/
Profit Loss
/
CORONA Remedies Profit & Loss

CORONA Remedies Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
₹422 Cr₹353 Cr₹342 Cr₹361 Cr₹347 Cr₹294 Cr₹298 Cr₹314 Cr
₹3 Cr₹4 Cr₹2 Cr₹2 Cr₹2 Cr₹1 Cr₹76 L₹2 Cr
₹426 Cr₹357 Cr₹345 Cr₹363 Cr₹349 Cr₹295 Cr₹298 Cr₹316 Cr
₹343 Cr₹301 Cr₹269 Cr₹292 Cr₹286 Cr₹250 Cr₹238 Cr₹256 Cr
₹96 Cr₹66 Cr₹85 Cr₹81 Cr₹72 Cr₹56 Cr₹70 Cr₹69 Cr
₹3 Cr₹1 Cr₹2 Cr₹2 Cr₹2 Cr₹2 Cr₹2 Cr₹3 Cr
₹80 Cr₹54 Cr₹55 Cr₹70 Cr₹61 Cr₹43 Cr₹58 Cr₹57 Cr
₹60 Cr₹45 Cr₹41 Cr₹52 Cr₹46 Cr₹31 Cr₹45 Cr₹43 Cr

Share Price Live Stats

Open (₹)2,163.40
Volume (₹)45,427.00
High (₹)2,163.40
Upper Circuit2,596.00
Low (₹)2,101.00
Lower Circuit1,730.80
Prev Close2,163.40
52W High (₹)2,292.40
Price2,118.00
52W Low (₹)1,336.60

Share Market Cap & Key Ratios Overview

M.Cap (₹)13237.20 Cr
Div. Yield (%)0.46
PE Ratio66.51
Debt to Equity0.19
Price to Book12.74
Book Value122.12
EPS (TTM)32.54
Face Value10.00
ROE (%)27.36

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
MANKINDNSE
DRREDDYNSE
AUROPHARMANSE
LUPINNSE
CORONANSE
LTP
1W Low
1W High
Market cap (₹)
1849.9+12.6 (0.69%)
1832.20
1891.50
4,47,476Cr
9602+227 (2.42%)
9312.50
9740
2,54,764Cr
4928.5+88.5 (1.83%)
4848.50
5010
1,89,423Cr
1180.3+20.3 (1.75%)
1152.10
1190.60
1,16,658Cr
1399+4.5 (0.32%)
1364.50
1419
1,11,484Cr
2026.2+72.2 (3.69%)
1963.80
2055.30
1,09,943Cr
2500+199.3 (8.66%)
2303
2504.30
1,01,712Cr
1200.4+15.4 (1.30%)
1185
1222
1,01,005Cr
1716-18 (-1.04%)
1689.30
1740
99,253Cr
2100.7+17.7 (0.85%)
2080
2135
96,031Cr
2118-83.8 (-3.81%)
2101
2247.90
13,237Cr

Key Highlights of CORONA Remedies Ltd’s P&L

In 2026-03-31, CORONA Remedies Ltd reported total revenue of ₹1413.83Cr, compared with ₹1202.35Cr in 2025-03-31, reflecting CORONA Remedies Ltd turnover.

Depreciation was ₹37.87Cr and finance costs were ₹6.97Cr in 2026-03-31

Profit Before Tax (PBT) has been ₹240.42Cr in 2026-03-31 as compared to ₹198.53Cr in 2025-03-31.

Net Profit (PAT) was ₹185.12Cr in 2026-03-31 compared with ₹149.43Cr in 2025-03-31.

Earnings per share (EPS) were ₹30.27 in 2026-03-31, compared with ₹24.43 in 2025-03-31.